 |
PDBsum entry 1suo
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Oxidoreductase
|
PDB id
|
|
|
|
1suo
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Oxidoreductase
|
 |
|
Title:
|
 |
Structure of mammalian cytochrome p450 2b4 with bound 4-(4- chlorophenyl)imidazole
|
|
Structure:
|
 |
Cytochrome p450 2b4. Chain: a. Synonym: cypiib4, p450-lm2, isozyme 2, p450 types b0 and b1. Engineered: yes. Mutation: yes. Other_details: cys 436 binds heme iron. 4-(4-chlorophenyl)imidazole is bound in the active site coordinating to the heme iron as the sixth ligand.
|
|
Source:
|
 |
Oryctolagus cuniculus. Rabbit. Organism_taxid: 9986. Gene: cyp2b4. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
Resolution:
|
 |
|
1.90Å
|
R-factor:
|
0.215
|
R-free:
|
0.239
|
|
|
Authors:
|
 |
E.E.Scott,M.A.White,Y.A.He,E.F.Johnson,C.D.Stout,J.R.Halpert
|
Key ref:
|
 |
E.E.Scott
et al.
(2004).
Structure of mammalian cytochrome P450 2B4 complexed with 4-(4-chlorophenyl)imidazole at 1.9-A resolution: insight into the range of P450 conformations and the coordination of redox partner binding.
J Biol Chem,
279,
27294-27301.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
26-Mar-04
|
Release date:
|
20-Jul-04
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P00178
(CP2B4_RABIT) -
Cytochrome P450 2B4 from Oryctolagus cuniculus
|
|
|
|
Seq: Struc:
|
 |
 |
 |
491 a.a.
465 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 3 residue positions (black
crosses)
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.1.14.14.1
- unspecific monooxygenase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
an organic molecule + reduced [NADPH--hemoprotein reductase] + O2 = an alcohol + oxidized [NADPH--hemoprotein reductase] + H2O + H+
|
 |
 |
 |
 |
 |
organic molecule
|
+
|
reduced [NADPH--hemoprotein reductase]
|
+
|
O2
|
=
|
alcohol
|
+
|
oxidized [NADPH--hemoprotein reductase]
|
+
|
H2O
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Cofactor:
|
 |
Heme-thiolate
|
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
J Biol Chem
279:27294-27301
(2004)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structure of mammalian cytochrome P450 2B4 complexed with 4-(4-chlorophenyl)imidazole at 1.9-A resolution: insight into the range of P450 conformations and the coordination of redox partner binding.
|
|
E.E.Scott,
M.A.White,
Y.A.He,
E.F.Johnson,
C.D.Stout,
J.R.Halpert.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
A 1.9-A molecular structure of the microsomal cytochrome P450 2B4 with the
specific inhibitor 4-(4-chlorophenyl)imidazole (CPI) in the active site was
determined by x-ray crystallography. In contrast to the previous experimentally
determined 2B4 structure, this complex adopted a closed conformation similar to
that observed for the mammalian 2C enzymes. The differences between the open and
closed structures of 2B4 were primarily limited to the lid domain of helices F
through G, helices B' and C, the N terminus of helix I, and the beta(4) region.
These large-scale conformational changes were generally due to the relocation of
conserved structural elements toward each other with remarkably little
remodeling at the secondary structure level. For example, the F' and G' helices
were maintained with a sharp turn between them but are placed to form the
exterior ceiling of the active site in the CPI complex. CPI was closely
surrounded by residues from substrate recognition sites 1, 4, 5, and 6 to form a
small, isolated hydrophobic cavity. The switch from open to closed conformation
dramatically relocated helix C to a more proximal position. As a result, heme
binding interactions were altered, and the putative NADPH-cytochrome P450
reductase binding site was reformed. This suggests a structural mechanism
whereby ligand-induced conformational changes may coordinate catalytic activity.
Comparison of the 2B4/CPI complex with the open 2B4 structure yields insights
into the dynamics involved in substrate access, tight inhibitor binding, and
coordination of substrate and redox partner binding.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Divergent (walleye) stereo view of cytochrome P450
2B4dH(H226Y) with CPI bound. The sequence can be traced from the
blue N terminus to the red C terminus. Major helices and termini
are labeled. Heme and CPI are shown in red and cyan sticks,
respectively. Images generated using PyMOL (www.pymol.org) (41)
unless otherwise credited.
|
 |
Figure 7.
Changes in the position of the C helix and heme ligation upon
CPI binding shown in divergent (walleye) stereo. Residues in
helix C (ribbon) alter positions significantly between the 2B4
open (green) and the CPI closed (blue) conformations, resulting
in the loss of a hydrogen bond to the D ring propionate in the
open conformation. Hydrogen bonds between the D ring propionate
and helix C residues are indicated by dashed lines. Residues
Arg-98 (R98), Ser-430 (S430), Arg-434 (R434), and His-369 (H369)
have smaller changes in their positions and are labeled once
near the base of the side chain.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2004,
279,
27294-27301)
copyright 2004.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
W.Li,
J.Shen,
G.Liu,
Y.Tang,
and
T.Hoshino
(2011).
Exploring coumarin egress channels in human cytochrome P450 2A6 by random acceleration and steered molecular dynamics simulations.
|
| |
Proteins,
79,
271-281.
|
 |
|
|
|
|
 |
Y.T.Lee,
E.C.Glazer,
R.F.Wilson,
C.D.Stout,
and
D.B.Goodin
(2011).
Three clusters of conformational States in p450cam reveal a multistep pathway for closing of the substrate access channel .
|
| |
Biochemistry,
50,
693-703.
|
 |
|
|
|
|
 |
H.Ouellet,
J.B.Johnston,
and
P.R.Ortiz de Montellano
(2010).
The Mycobacterium tuberculosis cytochrome P450 system.
|
| |
Arch Biochem Biophys,
493,
82-95.
|
 |
|
|
|
|
 |
J.F.Cotten,
S.A.Forman,
J.K.Laha,
G.D.Cuny,
S.S.Husain,
K.W.Miller,
H.H.Nguyen,
E.W.Kelly,
D.Stewart,
A.Liu,
and
D.E.Raines
(2010).
Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function.
|
| |
Anesthesiology,
112,
637-644.
|
 |
|
|
|
|
 |
L.E.Thornton,
S.G.Rupasinghe,
H.Peng,
M.A.Schuler,
and
M.M.Neff
(2010).
Arabidopsis CYP72C1 is an atypical cytochrome P450 that inactivates brassinosteroids.
|
| |
Plant Mol Biol,
74,
167-181.
|
 |
|
|
|
|
 |
N.Hanioka,
M.Yamamoto,
T.Tanaka-Kagawa,
H.Jinno,
and
S.Narimatsu
(2010).
Functional characterization of human cytochrome P4502E1 allelic variants: in vitro metabolism of benzene and toluene by recombinant enzymes expressed in yeast cells.
|
| |
Arch Toxicol,
84,
363-371.
|
 |
|
|
|
|
 |
N.Krishnamoorthy,
P.Gajendrarao,
S.Thangapandian,
Y.Lee,
and
K.W.Lee
(2010).
Probing possible egress channels for multiple ligands in human CYP3A4: a molecular modeling study.
|
| |
J Mol Model,
16,
607-614.
|
 |
|
|
|
|
 |
N.N.Bumpus,
and
P.F.Hollenberg
(2010).
Cross-linking of human cytochrome P450 2B6 to NADPH-cytochrome P450 reductase: Identification of a potential site of interaction.
|
| |
J Inorg Biochem,
104,
485-488.
|
 |
|
|
|
|
 |
N.Shakunthala
(2010).
New cytochrome P450 mechanisms: implications for understanding molecular basis for drug toxicity at the level of the cytochrome.
|
| |
Expert Opin Drug Metab Toxicol,
6,
1.
|
 |
|
|
|
|
 |
O.Shoji,
T.Fujishiro,
S.Nagano,
S.Tanaka,
T.Hirose,
Y.Shiro,
and
Y.Watanabe
(2010).
Understanding substrate misrecognition of hydrogen peroxide dependent cytochrome P450 from Bacillus subtilis.
|
| |
J Biol Inorg Chem,
15,
1331-1339.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
T.C.Pochapsky,
S.Kazanis,
and
M.Dang
(2010).
Conformational plasticity and structure/function relationships in cytochromes P450.
|
| |
Antioxid Redox Signal,
13,
1273-1296.
|
 |
|
|
|
|
 |
H.L.Lin,
H.Zhang,
K.R.Noon,
and
P.F.Hollenberg
(2009).
Mechanism-based inactivation of CYP2B1 and its F-helix mutant by two tert-butyl acetylenic compounds: covalent modification of prosthetic heme versus apoprotein.
|
| |
J Pharmacol Exp Ther,
331,
392-403.
|
 |
|
|
|
|
 |
H.Zhang,
C.Kenaan,
D.Hamdane,
G.H.Hoa,
and
P.F.Hollenberg
(2009).
Effect of conformational dynamics on substrate recognition and specificity as probed by the introduction of a de novo disulfide bond into cytochrome P450 2B1.
|
| |
J Biol Chem,
284,
25678-25686.
|
 |
|
|
|
|
 |
I.G.Denisov,
D.J.Frank,
and
S.G.Sligar
(2009).
Cooperative properties of cytochromes P450.
|
| |
Pharmacol Ther,
124,
151-167.
|
 |
|
|
|
|
 |
L.H.Xu,
S.Fushinobu,
H.Ikeda,
T.Wakagi,
and
H.Shoun
(2009).
Crystal structures of cytochrome P450 105P1 from Streptomyces avermitilis: conformational flexibility and histidine ligation state.
|
| |
J Bacteriol,
191,
1211-1219.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.Balaz
(2009).
Modeling kinetics of subcellular disposition of chemicals.
|
| |
Chem Rev,
109,
1793-1899.
|
 |
|
|
|
|
 |
S.C.Gay,
L.Sun,
K.Maekawa,
J.R.Halpert,
and
C.D.Stout
(2009).
Crystal structures of cytochrome P450 2B4 in complex with the inhibitor 1-biphenyl-4-methyl-1H-imidazole: ligand-induced structural response through alpha-helical repositioning.
|
| |
Biochemistry,
48,
4762-4771.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
D.F.Lewis,
and
Y.Ito
(2008).
Human cytochromes P450 in the metabolism of drugs: new molecular models of enzyme-substrate interactions.
|
| |
Expert Opin Drug Metab Toxicol,
4,
1181-1186.
|
 |
|
|
|
|
 |
D.R.Davydov,
N.Y.Davydova,
and
J.R.Halpert
(2008).
Allosteric transitions in cytochrome P450eryF explored with pressure-perturbation spectroscopy, lifetime FRET, and a novel fluorescent substrate, Fluorol-7GA.
|
| |
Biochemistry,
47,
11348-11359.
|
 |
|
|
|
|
 |
G.Niu,
Z.Wen,
S.G.Rupasinghe,
R.S.Zeng,
M.R.Berenbaum,
and
M.A.Schuler
(2008).
Aflatoxin B1 detoxification by CYP321A1 in Helicoverpa zea.
|
| |
Arch Insect Biochem Physiol,
69,
32-45.
|
 |
|
|
|
|
 |
J.D'Agostino,
X.Zhang,
H.Wu,
G.Ling,
S.Wang,
Q.Y.Zhang,
F.Liu,
and
X.Ding
(2008).
Characterization of CYP2A13*2, a variant cytochrome P450 allele previously found to be associated with decreased incidences of lung adenocarcinoma in smokers.
|
| |
Drug Metab Dispos,
36,
2316-2323.
|
 |
|
|
|
|
 |
J.D.Maréchal,
C.A.Kemp,
G.C.Roberts,
M.J.Paine,
C.R.Wolf,
and
M.J.Sutcliffe
(2008).
Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions.
|
| |
Br J Pharmacol,
153,
S82-S89.
|
 |
|
|
|
|
 |
K.N.Myasoedova
(2008).
New findings in studies of cytochromes P450.
|
| |
Biochemistry (Mosc),
73,
965-969.
|
 |
|
|
|
|
 |
M.A.White,
N.Mast,
I.Bjorkhem,
E.F.Johnson,
C.D.Stout,
and
I.A.Pikuleva
(2008).
Use of complementary cation and anion heavy-atom salt derivatives to solve the structure of cytochrome P450 46A1.
|
| |
Acta Crystallogr D Biol Crystallogr,
64,
487-495.
|
 |
|
|
|
|
 |
M.S.Achary,
and
H.A.Nagarajam
(2008).
Comparative docking studies of CYP1b1 and its PCG-associated mutant forms.
|
| |
J Biosci,
33,
699-713.
|
 |
|
|
|
|
 |
N.Mast,
M.A.White,
I.Bjorkhem,
E.F.Johnson,
C.D.Stout,
and
I.A.Pikuleva
(2008).
Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain.
|
| |
Proc Natl Acad Sci U S A,
105,
9546-9551.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
N.N.Bumpus,
and
P.F.Hollenberg
(2008).
Investigation of the mechanisms underlying the differential effects of the K262R mutation of P450 2B6 on catalytic activity.
|
| |
Mol Pharmacol,
74,
990-999.
|
 |
|
|
|
|
 |
N.Oezguen,
S.Kumar,
A.Hindupur,
W.Braun,
B.K.Muralidhara,
and
J.R.Halpert
(2008).
Identification and analysis of conserved sequence motifs in cytochrome P450 family 2. Functional and structural role of a motif 187RFDYKD192 in CYP2B enzymes.
|
| |
J Biol Chem,
283,
21808-21816.
|
 |
|
|
|
|
 |
R.Davydov,
R.Razeghifard,
S.C.Im,
L.Waskell,
and
B.M.Hoffman
(2008).
Characterization of the microsomal cytochrome P450 2B4 O2 activation intermediates by cryoreduction and electron paramagnetic resonance.
|
| |
Biochemistry,
47,
9661-9666.
|
 |
|
|
|
|
 |
S.Ekins,
M.Iyer,
M.D.Krasowski,
and
E.D.Kharasch
(2008).
Molecular characterization of CYP2B6 substrates.
|
| |
Curr Drug Metab,
9,
363-373.
|
 |
|
|
|
|
 |
U.M.Kent,
C.Sridar,
G.Spahlinger,
and
P.F.Hollenberg
(2008).
Modification of serine 360 by a reactive intermediate of 17-alpha-ethynylestradiol results in mechanism-based inactivation of cytochrome P450s 2B1 and 2B6.
|
| |
Chem Res Toxicol,
21,
1956-1963.
|
 |
|
|
|
|
 |
W.Li,
Y.Tang,
H.Liu,
J.Cheng,
W.Zhu,
and
H.Jiang
(2008).
Probing ligand binding modes of human cytochrome P450 2J2 by homology modeling, molecular dynamics simulation, and flexible molecular docking.
|
| |
Proteins,
71,
938-949.
|
 |
|
|
|
|
 |
Y.T.Meharenna,
K.E.Slessor,
S.M.Cavaignac,
T.L.Poulos,
and
J.J.De Voss
(2008).
The critical role of substrate-protein hydrogen bonding in the control of regioselective hydroxylation in p450cin.
|
| |
J Biol Chem,
283,
10804-10812.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.W.Munro,
H.M.Girvan,
and
K.J.McLean
(2007).
Variations on a (t)heme--novel mechanisms, redox partners and catalytic functions in the cytochrome P450 superfamily.
|
| |
Nat Prod Rep,
24,
585-609.
|
 |
|
|
|
|
 |
D.Cheng,
D.Harris,
J.R.Reed,
and
W.L.Backes
(2007).
Inhibition of CYP2B4 by 2-ethynylnaphthalene: evidence for the co-binding of substrate and inhibitor within the active site.
|
| |
Arch Biochem Biophys,
468,
174-182.
|
 |
|
|
|
|
 |
D.R.Davydov,
B.J.Baas,
S.G.Sligar,
and
J.R.Halpert
(2007).
Allosteric mechanisms in cytochrome P450 3A4 studied by high-pressure spectroscopy: pivotal role of substrate-induced changes in the accessibility and degree of hydration of the heme pocket.
|
| |
Biochemistry,
46,
7852-7864.
|
 |
|
|
|
|
 |
G.I.Lepesheva,
M.Seliskar,
C.G.Knutson,
N.V.Stourman,
D.Rozman,
and
M.R.Waterman
(2007).
Conformational dynamics in the F/G segment of CYP51 from Mycobacterium tuberculosis monitored by FRET.
|
| |
Arch Biochem Biophys,
464,
221-227.
|
 |
|
|
|
|
 |
H.Fernando,
D.R.Davydov,
C.C.Chin,
and
J.R.Halpert
(2007).
Role of subunit interactions in P450 oligomers in the loss of homotropic cooperativity in the cytochrome P450 3A4 mutant L211F/D214E/F304W.
|
| |
Arch Biochem Biophys,
460,
129-140.
|
 |
|
|
|
|
 |
J.P.Harrelson,
K.R.Henne,
D.O.Alonso,
and
S.D.Nelson
(2007).
A comparison of substrate dynamics in human CYP2E1 and CYP2A6.
|
| |
Biochem Biophys Res Commun,
352,
843-849.
|
 |
|
|
|
|
 |
L.Sun,
C.S.Chen,
D.J.Waxman,
H.Liu,
J.R.Halpert,
and
S.Kumar
(2007).
Re-engineering cytochrome P450 2B11dH for enhanced metabolism of several substrates including the anti-cancer prodrugs cyclophosphamide and ifosfamide.
|
| |
Arch Biochem Biophys,
458,
167-174.
|
 |
|
|
|
|
 |
P.Lafite,
F.André,
D.C.Zeldin,
P.M.Dansette,
and
D.Mansuy
(2007).
Unusual regioselectivity and active site topology of human cytochrome P450 2J2.
|
| |
Biochemistry,
46,
10237-10247.
|
 |
|
|
|
|
 |
S.G.Rupasinghe,
H.Duan,
and
M.A.Schuler
(2007).
Molecular definitions of fatty acid hydroxylases in Arabidopsis thaliana.
|
| |
Proteins,
68,
279-293.
|
 |
|
|
|
|
 |
S.Sansen,
M.H.Hsu,
C.D.Stout,
and
E.F.Johnson
(2007).
Structural insight into the altered substrate specificity of human cytochrome P450 2A6 mutants.
|
| |
Arch Biochem Biophys,
464,
197-206.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
T.N.Tsalkova,
N.Y.Davydova,
J.R.Halpert,
and
D.R.Davydov
(2007).
Mechanism of interactions of alpha-naphthoflavone with cytochrome P450 3A4 explored with an engineered enzyme bearing a fluorescent probe.
|
| |
Biochemistry,
46,
106-119.
|
 |
|
|
|
|
 |
W.Mao,
M.A.Schuler,
and
M.R.Berenbaum
(2007).
Cytochrome P450s in Papilio multicaudatus and the transition from oligophagy to polyphagy in the Papilionidae.
|
| |
Insect Mol Biol,
16,
481-490.
|
 |
|
|
|
|
 |
Y.J.Jang,
E.Y.Cha,
W.Y.Kim,
S.W.Park,
J.H.Shon,
S.S.Lee,
and
J.G.Shin
(2007).
CYP2S1 gene polymorphisms in a Korean population.
|
| |
Ther Drug Monit,
29,
292-298.
|
 |
|
|
|
|
 |
Y.Zhao,
L.Sun,
B.K.Muralidhara,
S.Kumar,
M.A.White,
C.D.Stout,
and
J.R.Halpert
(2007).
Structural and thermodynamic consequences of 1-(4-chlorophenyl)imidazole binding to cytochrome P450 2B4.
|
| |
Biochemistry,
46,
11559-11567.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.D.Favia,
A.Cavalli,
M.Masetti,
A.Carotti,
and
M.Recanatini
(2006).
Three-dimensional model of the human aromatase enzyme and density functional parameterization of the iron-containing protoporphyrin IX for a molecular dynamics study of heme-cysteinato cytochromes.
|
| |
Proteins,
62,
1074-1087.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Hindupur,
D.Liu,
Y.Zhao,
H.D.Bellamy,
M.A.White,
and
R.O.Fox
(2006).
The crystal structure of the E. coli stress protein YciF.
|
| |
Protein Sci,
15,
2605-2611.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Seifert,
S.Tatzel,
R.D.Schmid,
and
J.Pleiss
(2006).
Multiple molecular dynamics simulations of human p450 monooxygenase CYP2C9: the molecular basis of substrate binding and regioselectivity toward warfarin.
|
| |
Proteins,
64,
147-155.
|
 |
|
|
|
|
 |
D.E.Prosser,
Y.Guo,
Z.Jia,
and
G.Jones
(2006).
Structural motif-based homology modeling of CYP27A1 and site-directed mutational analyses affecting vitamin D hydroxylation.
|
| |
Biophys J,
90,
3389-3409.
|
 |
|
|
|
|
 |
D.F.Lewis,
B.G.Lake,
Y.Ito,
and
P.Anzenbacher
(2006).
Quantitative structure-activity relationships (QSARs) within cytochromes P450 2B (CYP2B) subfamily enzymes: the importance of lipophilicity for binding and metabolism.
|
| |
Drug Metabol Drug Interact,
21,
213-231.
|
 |
|
|
|
|
 |
M.Ekroos,
and
T.Sjögren
(2006).
Structural basis for ligand promiscuity in cytochrome P450 3A4.
|
| |
Proc Natl Acad Sci U S A,
103,
13682-13687.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.J.de Groot
(2006).
Designing better drugs: predicting cytochrome P450 metabolism.
|
| |
Drug Discov Today,
11,
601-606.
|
 |
|
|
|
|
 |
R.Singh,
M.A.White,
K.V.Ramana,
J.M.Petrash,
S.J.Watowich,
A.Bhatnagar,
and
S.K.Srivastava
(2006).
Structure of a glutathione conjugate bound to the active site of aldose reductase.
|
| |
Proteins,
64,
101-110.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
U.M.Kent,
H.L.Lin,
D.E.Mills,
K.A.Regal,
and
P.F.Hollenberg
(2006).
Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6.
|
| |
Chem Res Toxicol,
19,
279-287.
|
 |
|
|
|
|
 |
W.M.Atkins
(2006).
Current views on the fundamental mechanisms of cytochrome P450 allosterism.
|
| |
Expert Opin Drug Metab Toxicol,
2,
573-579.
|
 |
|
|
|
|
 |
A.E.Rettie,
and
J.P.Jones
(2005).
Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics.
|
| |
Annu Rev Pharmacol Toxicol,
45,
477-494.
|
 |
|
|
|
|
 |
D.A.Schultz,
A.M.Friedman,
M.A.White,
and
R.O.Fox
(2005).
The crystal structure of the cis-proline to glycine variant (P114G) of ribonuclease A.
|
| |
Protein Sci,
14,
2862-2870.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
E.Hazai,
Z.Bikádi,
M.Simonyi,
and
D.Kupfer
(2005).
Association of cytochrome P450 enzymes is a determining factor in their catalytic activity.
|
| |
J Comput Aided Mol Des,
19,
271-285.
|
 |
|
|
|
|
 |
K.Schleinkofer,
Sudarko,
P.J.Winn,
S.K.Lüdemann,
and
R.C.Wade
(2005).
Do mammalian cytochrome P450s show multiple ligand access pathways and ligand channelling?
|
| |
EMBO Rep,
6,
584-589.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |